B cell acute lymphoblastic leukemia following mild COVID-19 in an 11-year-old boy (preprint)

Coronavirus disease-2019 (COVID-19) has infected millions of people with high lethality in the world, but little is known whether severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has impacts on triggering pediatric acute lymphoblastic leukemia (ALL). We present a case of a child with atypical clinical manifestation who developed B-cell acute lymphoblastic leukemia following a mild symptomatic COVID-19 infection. This case underlines the risks of potential oncogenic effects with the history of this viral infection and a state of immunosuppression.

A Novel Amplification-free SARS-CoV-2 Point-of-care Nucleic Acid Detection System based on Hybrid Capture Fluorescence Immunoassay (preprint)

Herein we presented a novel, rapid and amplification-free SARS-CoV-2 nucleic acid detection system based on hybrid capture fluorescence immunoassay (HC-FIA) technology. The usage of the monoclonal antibody S9.6 in recognizing DNA-RNA double-stranded hybrids enabled the conversion of nucleic acid testing into immunofluorescence carrying on a simple lateral flow dipstick. The established HC-FIA also exhibited satisfactory sensitivity, specificity and great robustness. The clinical evaluation of HC-FIA kit and fluorescence reading device are further processed in three hospitals independently. The results of 734 samples from 670 subjects indicated high consistency between our HC-FIA and quantitative polymerase chain reaction based commercially available kit or clinical diagnosis according to Kappa statistics. Altogether, HC-FIA related method and commercial test kit show unparalleled advantages as time saving, amplification-free, high throughput and portable POCT molecular diagnosis, which facilitates its application as on-site Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleic acid detection in epidemic prevention and control worldwide, especially during the outbreak.